Address
1 Corporate Drive
South San Francisco, CA 94080

Contact
contact@soley.ai

22 May 2023

Breakthrough Gene Editing Technology Discovered

Mask Group 63 2@2x
Call-to-Action

More Articles

Dan Von Hoff, M.D.

  • 30+ years pioneer in oncology drug development
  • Distinguished Professor and Physician in Chief, Translational Genomics Research Institute
  • Professor of Medicine at University of Arizona and Mayo Clinic
  • Former National Cancer Advisory Board Member
  • Past President of the American Association for Cancer Research
  • Contributed to development of Abraxane®(nab-paclitaxel), Camptosar® irinotecan, Gemzar® gemcitabine and many other

Afsaneh Naimollah

Linkedin
  • 30+ years of experience corporate finance, strategy advisory and investment banking
  • Executive in Residence, Plug and Play Tech Center
  • Managing Partner, XEN Partners
  • Former Global Head of Barclays Capital Technology Group

Leo Grady, PhD

Linkedin
  • 20+ years of industry experience leading AI/ML, computer vision, and digital health tech
  • Founder and CEO, Stealth AI healthcare company
  • Former CEO of PaigeAI
  • Former SVP of Engineering, Heartflow
  • Founder and CEO of Jona
  • CEO in Residence at Breyer Capital

Fei-Fei Li, PhD

Linkedin
  • Sequoia Professor of Computer Science, Stanford University
  • Co-Director, Stanford Human Centered AI Institute
  • Creator of ImageNet
  • Co-Founder, Chairperson of the Board, AI4ALL
  • Former Chief Scientist of AI/ML, VP Google

Peter Libby, MD

Linkedin
  • Mallinckrodt Professor of Medicine, Cardiovascular Specialist, Harvard Medical School and Brigham and Women’s Hospital
  • World renowned expert in atherosclerosis, cardiovascular medicine and clonal hematopoiesis of indeterminate potential

Keith Flaherty, MD

  • Professor of Medicine, Harvard Medical School
  • Director of Clinical Research, Cancer Center, Massachusetts General Hospital
  • 25+ years expertise in oncology research, drug development, and targeted cancer therapies
  • Co-founder of Loxo Oncology, X4-Pharma, Strata Oncology, Apricity Oncology, Scorpion Therapeutics

Clay Johnston, MD, PhD

Linkedin
  • Professor of Neurology
  • Inaugural Dean, Dell Medical School, UT Austin
  • Former Associate Vice Chancellor of Research, UCSF
  • Co-Founder, Harbor Health

Tony Adamis, MD

  • 30+ years of industry R&D experience
  • Former SVP, Development Innovation, Genentech
  • Co-discovery of VEGF in ocular disease
  • Co-founder, Director, EyeBio

Antoine Yver, MD

Linkedin
  • 30+ years experience and world leader in oncology drug development
  • Board Member, Sanofi
  • Former Head of Oncology Global Medicine Development, AstraZeneca
  • Former Chairman of Development, Centessa
  • Former EVP, Global Head of Oncology R&D, Daiichi Sankyo
  • Contributed to development of Tagrisso® osimertinib, Lynparza® olaparib, Enhertu® trastuzumab deruxtecan and many other

Dan Von Hoff, MD

Co-Founder, CEO, Board Member

Linkedin
  • 30 years of academic experience in patient care, teaching, clinical/basic and stem cell research
  • Expertise in physiologic cellular stress, stem cells, cardiomyocytes, and neuronal cells
  • The Johns Hopkins School of Medicine (1995): M.D.
  • Harvard Medical School / Brigham and Women’s Hospital (1995-2003): internship, residency, chief residency, general and interventional cardiology
  • UCSF (since 2003): Translational Cardiac Stem Cell Program: Founder and Director